AMENDMENTS

IN THE CLAIMS

Please rewrite the claims as follows:

37. (Amended) A prodrug comprising a drug moiety bound to a carrier framework having the formula (Z):



wherein:

X= OH, OMe or $N(CH_3)_2$; and
n=0-3;

and;

R_1=H, C_{1-4} lower alkyl, or together with R_2 forms part of a cycloalkyl group which may be further substituted to form part of a polycyclic cycloalkyl group;

R_2=H, OMe, C_{1-4} lower alkyl, or together with R_1 and/or R_3 forms part of a cycloalkyl, polycyclic cycloalkyl, or forms part of a polycyclic aromatic group by linkage to R_4;

R_3=H, OMe, C_{1-4} lower alkyl or together with R_2 forms part of a cycloalkyl, polycyclic cycloalkyl; and

R_4=H or is fused directly to the aromatic position designated by R_2 and either:

the drug moiety is derived from a drug having a free amino, hydroxyl or mercapto group and which links it to the rest of the prodrug, such that A represents NH, NR (R=C_{1-4} lower alkyl), O or S; or

the drug moiety is derived from a drug having a carboxylate group, an ester linkage joining it to the rest of the prodrug and A being absent.

42. (Amended) A prodrug according to claim 37 wherein the framework includes a naphthyl group.

45. (Amended) A prodrug according to claim 44, having the general formula (Y):



R_2, R_3 and X being selected from any one of the group of:

a) R_2 = H, R_3 = H, X = OMe in Formula XVIII;

b) R_2 = H, R_3 = OMe, X = OMe in Formula XIX; and

c) R_2 = OMe, R_3 = H, X = OMe in Formula XXII.

48. A prodrug according to claim 47, having a formula of:

(XXX):



52. (Amended) A method of inhibiting tumor cell growth comprising:

contacting a tumor cell with a prodrug according to any one of claims 37 or 38, wherein the tumor cell comprises an enzyme having aromatic hydroxylase activity.

57. A prodrug comprising a drug moiety bound to a carrier framework having the formula selected from the group consisting of:

(XXXI):



and

(XXXII):